MedDay Pharmaceuticals GmbH to participate at the 90th Congress of the German Society of Neurology in Leipzig, Germany

Paris, France & Hamm, Germany, September 18 2017


MedDay Pharmaceuticals, a biotechnology company focused on the treatment of nervous system disorders, today announces that it will be participating at the 90th Congress of the German Society of Neurology (Kongress der Deutschen Gesellschaft für Neurologie; DGN) from September 20-23, 2017 in Leipzig, Germany.


MedDay will be exhibiting at booth No. D5.


The annual DGN congress is one of the three most highly attended neurological congresses worldwide. It is the main scientific, educational and discussion platform for neurological medicine in Germany, and is one of the largest German-speaking medical congresses. The event presents new information on the diagnosis, treatment and understanding of neurological diseases.

MedDay has a pioneering metabolic approach to the development of new drugs to treat central nervous system disorders. Utilizing its research platform, SPECMET, to explore naturally occurring metabolic pathways, MedDay is able to identify target compounds that have the potential to enhance cell functioning and cell self-regeneration capabilities in patients suffering from neurodegenerative disorders in areas of high unmet medical need.

MD1003, the Company’s lead product, is a high-dose Pharmaceutical-grade Biotin (hdPB) currently in development in Progressive Multiple Sclerosis and in other demyelinating diseases. MedDay’s R&D pipeline also includes MD1103 in autism spectrum disorders and MD1105 in Alzheimer’s disease.

MedDay is dedicated to serving patients and is moving towards its goal of building a fully integrated biotechnology company, operating from discovery to commercialisation.




About MedDay


MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer); and Guillaume Brion, MD (Chief Operating Officer). The Company’s most advanced pipeline candidate is MD1003 developed in progressive multiple sclerosis. MedDay is well funded by investors including Sofinnova Partners, InnoBio, Edmond de Rothschild Investment Partners and Bpifrance Large Venture.

MedDay is headquartered in Paris, with offices in Maidenhead (England), Boston (USA) and Hamm in North Rhine-Westphalia (Germany).


Our goals:


Discover and develop compounds targeting metabolic pathways to treat nervous system disorders in areas of high unmet medical need, including multiple sclerosis, Alzheimer’s disease, ALS and autism
Develop sound expertise in accelerated development
Establish strong academic and commercial collaborations with strategic partners to further expand our pipeline


Our expertise:


Our main areas of expertise are in progressive multiple sclerosis, Alzheimer’s disease, ALS and autism
Our metabolomics research platform, SPECMET, allows MedDay to examine brain metabolism in patients suffering from central nervous systems disorders from a new and unique angle
This exploration tool is able to identify new therapeutic targets by analysing the cerebrospinal fluid of patients suffering from central nervous system disorders through metabolomic and lipidomic analysis in order to identify disrupted metabolic pathways.


For more information, please see: Follow us on Twitter: @MedDayPharm.


Contact information:

MedDay Pharmaceuticals



MedDay Pharmaceuticals GmbH
Phone: +49 2381 4272003

Media Relations
Anne Hennecke
MC Services AG
Phone: +49 211 52925222